


Stage IV lung carcinoma with *EGFR*-activating mutation



**Figure 4.** Treatment algorithm for stage IV lung carcinoma with *EGFR*-activating mutation.

<sup>a</sup>MCBS score for the combination of bevacizumab with gefitinib or erlotinib.

<sup>b</sup>Not EMA-approved.